Signal Over 200 exosome clinical trials since 2022, with yields reported up to fifty-fold higher

Summary

The chapter's readiness evidence is threefold: manufacturing advances in the early 2020s that raised yields by up to fifty times and made clinical-scale production viable, classification of exosome therapies as biological medicinal products by the FDA and EMA while the approval framework is still being built, and more than 200 clinical trials launched since 2022 across cancer, neurological disease and long COVID.